These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21854277)

  • 1. Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.
    Oden NL; VanVeldhuisen PC; Wakim PG; Trivedi MH; Somoza E; Lewis D
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):350-7. PubMed ID: 21854277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies.
    Korte JE; Magruder KM; Chiuzan CC; Logan SL; Killeen T; Bandyopadhyay D; Brady KT
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):358-66. PubMed ID: 21854278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-report and urine drug screen concordance among women with co-occurring PTSD and substance use disorders participating in a clinical trial: Impact of drug type and participant characteristics.
    Ruglass LM; Shevorykin A; Zhao Y; Killeen TK; Bauer AG; Morgan-López AA; Back SE; Fitzpatrick S; López-Castro T; Norman SB; Saavedra LM; Hien DA
    Drug Alcohol Depend; 2023 Mar; 244():109769. PubMed ID: 36696843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study.
    Trivedi MH; Greer TL; Rethorst CD; Carmody T; Grannemann BD; Walker R; Warden D; Shores-Wilson K; Stoutenberg M; Oden N; Silverstein M; Hodgkins C; Love L; Seamans C; Stotts A; Causey T; Szucs-Reed RP; Rinaldi P; Myrick H; Straus M; Liu D; Lindblad R; Church T; Blair SN; Nunes EV
    J Clin Psychiatry; 2017; 78(8):1075-1082. PubMed ID: 28199070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does urine drug abuse screening help for managing patients? A systematic review.
    Dupouy J; Mémier V; Catala H; Lavit M; Oustric S; Lapeyre-Mestre M
    Drug Alcohol Depend; 2014 Mar; 136():11-20. PubMed ID: 24417964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037).
    Trivedi MH; Greer TL; Potter JS; Grannemann BD; Nunes EV; Rethorst C; Warden D; Ring KM; Somoza E
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):339-49. PubMed ID: 21854276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirically contrasting urine drug screening-based opioid use disorder treatment outcome definitions.
    Brandt L; Odom GJ; Hu MC; Castro C; Balise RR;
    Addiction; 2024 Jul; 119(7):1289-1300. PubMed ID: 38616571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine drug screen findings among ambulatory oncology patients in a supportive care clinic.
    Rauenzahn S; Sima A; Cassel B; Noreika D; Gomez TH; Ryan L; Wolf CE; Legakis L; Del Fabbro E
    Support Care Cancer; 2017 Jun; 25(6):1859-1864. PubMed ID: 28120116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.
    Lewis AL; Young GJ; Selman LE; Rice C; Clement C; Ochieng CA; Abrams P; Blair PS; Chapple C; Glazener CM; Horwood J; McGrath JS; Noble S; Taylor GT; Lane JA; Drake MJ
    Health Technol Assess; 2020 Sep; 24(42):1-122. PubMed ID: 32902375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically relevant characteristics associated with early treatment drug use versus abstinence.
    Cochran G; Stitzer M; Nunes EV; Hu MC; Campbell A
    Addict Sci Clin Pract; 2014 Apr; 9(1):6. PubMed ID: 24708748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of timeline follow-back self-report and oral fluid testing to detect substance use in adult primary care patients.
    Nordeck CD; Gryczynski J; O'Grady KE; Polak K; Svikis DS; McNeely J; Wu LT; Schwartz RP
    Drug Alcohol Depend; 2020 Apr; 209():107939. PubMed ID: 32114329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of women concordant and discordant for urine drug screens for cannabis exposure and self-reported cannabis use during pregnancy.
    Bogdan R; Leverett SD; Constantino-Petit AM; Lashley-Simms N; Liss DB; Johnson EC; Lenze SN; Lean RE; Smyser TA; Carter EB; Smyser CD; Rogers CE; Agrawal A
    Neurotoxicol Teratol; 2024; 103():107351. PubMed ID: 38604316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of urine drug screening: a clinical audit.
    Murnion BP; Granot R; Day RO
    Emerg Med Australas; 2007 Jun; 19(3):246-52. PubMed ID: 17564693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulant abuser groups to engage in 12-step: a multisite trial in the National Institute on Drug Abuse Clinical Trials Network.
    Donovan DM; Daley DC; Brigham GS; Hodgkins CC; Perl HI; Garrett SB; Doyle SR; Floyd AS; Knox PC; Botero C; Kelly TM; Killeen TK; Hayes C; Kau'i Baumhofer N; Seamans C; Zammarelli L
    J Subst Abuse Treat; 2013 Jan; 44(1):103-14. PubMed ID: 22657748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates and types of urine drug screen false negative results compared with confirmatory toxicology testing in major trauma patients.
    Weiss ST; Veach LJ; McGill W; Brent J
    Clin Toxicol (Phila); 2022 Oct; 60(10):1122-1129. PubMed ID: 36069771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline risk factors for drug use among African-American patients during first-month induction/stabilization on methadone.
    Lister JJ; Greenwald MK; Ledgerwood DM
    J Subst Abuse Treat; 2017 Jul; 78():15-21. PubMed ID: 28554598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of missing data methods for hypothesis tests of the treatment effect in substance abuse clinical trials: a Monte-Carlo simulation study.
    Hedden SL; Woolson RF; Malcolm RJ
    Subst Abuse Treat Prev Policy; 2008 Jun; 3():13. PubMed ID: 18522752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capturing drug use patterns at a glance: An n-ary word sufficient statistic for repeated univariate categorical values.
    Odom GJ; Brandt L; Castro C; Luo SX; Feaster DJ; Balise RR;
    PLoS One; 2023; 18(9):e0291248. PubMed ID: 37682922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.